Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 1
1949 1
1953 1
1954 4
1955 1
1956 1
1958 4
1959 2
1962 3
1963 2
1964 1
1965 2
1966 4
1967 1
1968 3
1970 1
1971 2
1972 2
1974 1
1975 4
1976 10
1977 4
1978 8
1979 5
1980 6
1981 4
1982 2
1983 2
1985 2
1986 1
1987 2
1988 6
1989 2
1990 4
1991 4
1992 6
1993 7
1994 4
1995 6
1996 4
1997 4
1998 4
1999 7
2000 6
2001 9
2002 8
2003 6
2004 8
2005 16
2006 20
2007 28
2008 42
2009 28
2010 31
2011 36
2012 51
2013 34
2014 61
2015 49
2016 48
2017 55
2018 62
2019 66
2020 87
2021 111
2022 120
2023 93
2024 38

Text availability

Article attribute

Article type

Publication date

Search Results

1,135 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Dazmin
Page 1
Immunotherapy for melanoma.
Cuevas LM, Daud AI. Cuevas LM, et al. Semin Cutan Med Surg. 2018 Jun;37(2):127-131. doi: 10.12788/j.sder.2018.028. Semin Cutan Med Surg. 2018. PMID: 30040090 Review.
Pediatric sedation.
Daud YN, Carlson DW. Daud YN, et al. Pediatr Clin North Am. 2014 Aug;61(4):703-17. doi: 10.1016/j.pcl.2014.05.003. Epub 2014 Jun 6. Pediatr Clin North Am. 2014. PMID: 25084719 Review.
Melanoma.
Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE 3rd, Daud A, Dilawari RA, Dimaio D, Guild V, Halpern AC, Hodi FS Jr, Kelley MC, Khushalani NI, Kudchadkar RR, Lange JR, Lind A, Martini MC, Olszanski AJ, Pruitt SK, Ross MI, Swetter SM, Tanabe KK, Thompson JA, Trisal V, Urist MM; National Comprehensive Cancer Network. Coit DG, et al. J Natl Compr Canc Netw. 2012 Mar;10(3):366-400. doi: 10.6004/jnccn.2012.0036. J Natl Compr Canc Netw. 2012. PMID: 22393197 No abstract available.
Melanoma risk during immunomodulating treatment.
Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Daud A, Algazi A, Rappersberger K, Ortiz-Urda S. Zheng YJ, et al. Melanoma Res. 2022 Dec 1;32(6):411-418. doi: 10.1097/CMR.0000000000000838. Epub 2022 Aug 22. Melanoma Res. 2022. PMID: 35993892 Review.
The Liver-Immunity Nexus and Cancer Immunotherapy.
Lee JC, Green MD, Huppert LA, Chow C, Pierce RH, Daud AI. Lee JC, et al. Clin Cancer Res. 2022 Jan 1;28(1):5-12. doi: 10.1158/1078-0432.CCR-21-1193. Epub 2021 Jul 20. Clin Cancer Res. 2022. PMID: 34285059 Free PMC article. Review.
Melanoma.
Houghton AN, Coit DG, Daud A, Dilawari RA, Dimaio D, Gollob JA, Haas NB, Halpern A, Johnson TM, Kashani-Sabet M, Kraybill WG, Lange JR, Martini M, Ross MI, Samlowski WE, Sener SF, Tanabe KK, Thompson JA, Trisal V, Urist MM, Walker MJ; National Comprehensive Cancer Network. Houghton AN, et al. J Natl Compr Canc Netw. 2006 Aug;4(7):666-84. doi: 10.6004/jnccn.2006.0057. J Natl Compr Canc Netw. 2006. PMID: 16884669 No abstract available.
Melanocytic Neoplasms, Introduction.
Daud AI. Daud AI. Semin Cutan Med Surg. 2018 Jun;37(2):87. doi: 10.12788/j.sder.2018.028. Semin Cutan Med Surg. 2018. PMID: 30040084 No abstract available.
Prognostic Biomarkers for Melanoma Immunotherapy.
Twitty CG, Huppert LA, Daud AI. Twitty CG, et al. Curr Oncol Rep. 2020 Feb 11;22(3):25. doi: 10.1007/s11912-020-0886-z. Curr Oncol Rep. 2020. PMID: 32048065 Review.
High Expression of MHC Class I Overcomes Cancer Immunotherapy Resistance Due to IFNγ Signaling Pathway Defects.
Kawase K, Kawashima S, Nagasaki J, Inozume T, Tanji E, Kawazu M, Hanazawa T, Togashi Y. Kawase K, et al. Cancer Immunol Res. 2023 Jul 5;11(7):895-908. doi: 10.1158/2326-6066.CIR-22-0815. Cancer Immunol Res. 2023. PMID: 37062030
Our results indicate that patients with IFNgamma signaling pathway defects are not always resistant to immune checkpoint inhibitors and highlight the importance of MHC-I expression among the pathways and the possibility of NF-kappaB-targeted therapies to overcome such resistance. …
Our results indicate that patients with IFNgamma signaling pathway defects are not always resistant to immune checkpoint inhibitors and high …
Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12.
Garris CS, Arlauckas SP, Kohler RH, Trefny MP, Garren S, Piot C, Engblom C, Pfirschke C, Siwicki M, Gungabeesoon J, Freeman GJ, Warren SE, Ong S, Browning E, Twitty CG, Pierce RH, Le MH, Algazi AP, Daud AI, Pai SI, Zippelius A, Weissleder R, Pittet MJ. Garris CS, et al. Immunity. 2022 Sep 13;55(9):1749. doi: 10.1016/j.immuni.2022.07.021. Immunity. 2022. PMID: 36103861 No abstract available.
1,135 results